Thymoma and Thymic Carcinoma
Conditions
Keywords
thymoma thymic carcinoma
Brief summary
Given the high expression of IGF-1R and pAKT proteins in thymoma tissues, able to sensitize tumors to mTOR inhibition, and the anticancer activity of the mTOR inhibitors, clinical evaluation in thymoma and thymic carcinoma seems to be very interesting. Patients will receive continuous treatment with oral everolimus 10 mg once daily. Efficacy and safety profile of Everolimus will be evaluated.
Detailed description
Patients will receive continuous treatment with oral everolimus 10 mg once daily. Study drug will be self-administered orally (two 5 mg tablets) daily in a fasting state or with a light fat-free meal. Each cycle will be considered as 21 days of treatment; safety was assessed every 21 days. Tumor assessement will be done every two cycles. Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal.
Interventions
DRUGEverolimus
Everolimus will be orally administered at the dosage of 10 mg once daily. Each cycle will be considered as 21 days of treatment. Tumor assessment will be done every two cycles.Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal.
Sponsors
Armando Santoro, MD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological diagnosis of invasive recurrent or metastatic thymoma or thymic carcinoma confirmed by pathologist. * At least one prior platinum-containing chemotherapy regimen. There is no limit to the number of prior chemotherapy regimens received. Progressive disease should have been documented before entry into the study. * Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than 20 mm with conventional techniques or as greater than 10 mm with spiral CT scan. * Patients must have recovered from toxicity related to prior therapy to at least to grade 1 (defined by CTCAE 3.0). * No major surgery, radiation therapy, chemotherapy, biologic therapy (including any investigational agents), or hormonal therapy (other than replacement), within 4 weeks prior to entering the study. * Life expectancy of at least 3 months. * Performance status (ECOG)\<=2 * Negative pregnancy test (if female in reproductive years) * Adequate organ and marrow function (as defined below) * Leukocytes \>=3,000/mm, Absolute neutrophil count \>=1,500/mm, Hemoglobin\>= 9 g/dL, Platelets\>= 100,000/mm, Total bilirubin \>= 1.5 x institutional upper limit of normal (ULN), AST(SGOT)/ALT(SGPT)\>= 3 x institutional ULN (5x if LFT elevations due to liver metastases, )Creatinine \<= 1.5 x institutional ULN
Exclusion criteria
* Patients with symptomatic brain metastases. However, patients who have had treatment for their brain metastases and whose brain metastatic disease status has remained stable for at least 3 months without steroids may be enrolled at the discretion of the investigator. * Major surgery, other than diagnostic surgery, within 4 weeks prior to treatment * Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy * Pregnant or breast feeding women * Previous (within the last 5 years) or current malignancies at other sites, except for adequately treated basal cell or squamous cell skin cancer or in situ carcinoma of the cervix uteri * Current enrollment in or participation in another therapeutic clinical trial within 4 weeks preceding treatment start. * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgement of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| disease control rate | 6 months | disease control rate (DCR), considered as complete response (CR) plus partial response (PR) plus stable disease (SD), of Everolimus monotherapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response | 6 months | This endpoint is assessed in patients whose best tumor response is CR or PR as the time from the date of the first documentation of confirmed objective tumor response to the date of first documentation of objective tumor progression, objective tumor recurrence, or of death due progressive disease, whichever comes first |
| OS | 6 months | Overall Survival (OS) will be evaluated from the date of treatment start until the date of death or last contact for patients alive at the end of the study. |
| PFS | 6 months | Progression free survival (PFS) will be evaluated from the date of treatment start until the date of progression or death whichever occurs first, otherwise until the last visit date. |
| safety profile | 6 months | Overall safety profile, evaluated on the basis of laboratory and clinical safety parameters |
| biomarkers expression | 6 months | To perform immunohistochemistry for IGF-1R, pAKT ,mTOR, p-S6K, p-S6, p-4E-BP1, and pTEN expression in all pre-treatment tissue specimens of thymoma and thymic carcinoma and correlate with response and survival (PFS and OS). |
| FDG-PET imaging relations | 6 weeks | To correlate response to therapy with changes in FDG-PET imaging at baseline and first restaging. |
Countries
Italy
Outcome results
None listed